

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/464,303	ATTY. DOCKET NO.: A0752.70001US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: December 15, 1999	CONFIRMATION NO.: 7348
		APPLICANT: Stahl, et al.	
		GROUP ART UNIT: 1644	EXAMINER: Vander Vegt, Francois P.
Sheet	1	of	1

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/PVI/		5,616,311		Yen	04-01-1997

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
/PVI/ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓		LEKOWSKI, R.W. et al., "Ulex europaeus Agglutinin II (UEA-II) is a Novel, Potent Inhibitor of Complement Activation on Human Endothelial Cells", <i>Circulation</i> , November 2, 1999, Vol. 110, No. 18 Suppl., Page I.259, Meeting Info: 72 nd Scientific Sessions of the American Heart Association, Atlanta, Georgia, USA, November 7-10, 1999		
		Office communication from USPTO, Application No. 09/638,420 mailed January 14, 2003		
		Office communication from USPTO, Application No. 09/638,420 mailed October 21, 2003		
		International Search Report PCT/US00/22123, mailed on November 26, 2001		
		Written Opinion, PCT/US00/22123, mailed on September 27, 2001		
		Written Opinion, PCT/US00/22123, mailed on September 21, 2001		
		Written Opinion, PCT/US00/22123, mailed on March 30, 2001		
		International Search Report PCT/US00/22123, mailed on December 29, 2000		
		MATSUSHITA, M., et al. "Human mannose-binding protein is identical to a component of Ra-reactive factor", <i>Biochemical and Biophysical Research Communications</i> , Vol. 183, No. 2, pgs. 645-651, March 16, 1992		

EXAMINER /F. Pierre VanderVegt/	DATE CONSIDERED 03/28/2007
------------------------------------	-------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. § 120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/464,303		ATTY. DOCKET NO.: A0752.70001US00	
				FILING DATE: December 15, 1999		CONFIRMATION NO.: 7348	
				APPLICANT: Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Francois P. Vandervegt	
Sheet	1	of	3				

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/PV/ ↓	C82	Collard CD, Büküsoglu C, Sperati CJ, Colgan SP, Stahl GL. Reoxygenation of hypoxic human umbilical vein endothelial cells (HUVECs) activates the classical complement (C) pathway. FASEB J. 1996; 10:A621 – ABSTRACT ONLY	
	C83	Väkevä AP, Collard CD, Büküsoglu C, Stahl GL. Complement regulation and activation following hypoxia and reoxygenation of human umbilical vein endothelial cells (HUVECs). FASEB J. 1996; 10:A622 – ABSTRACT ONLY	
	C84	Collard CD and Stahl GL. Deposition of the terminal complement complex (C5b-9) on human umbilical vein endothelial cells (HUVECs) following hypoxia and reoxygenation decreases intracellular levels of cyclic-guanosine monophosphate (cGMP). Circulation 1996; 94:1105 – ABSTRACT ONLY	
	C85	Agah A, Väkevä AP, Morse DS, Rollins SA and Stahl GL. Complement induced apoptosis in vitro and in vivo. Role of the terminal complement complex, C5b-9. Microcirculation 1997;4:124. – ABSTRACT ONLY	
	C86	Collard CD and Stahl GL. Reoxygenation of hypoxic human umbilical vein endothelial cells (HUVECs) deposits C5b-9 and decreases intracellular cGMP. Microcirculation 1997;4:171 – ABSTRACT ONLY	
	C87	Väkevä AP, Morse DS, Rollins SA and Stahl GL. Reoxygenation of hypoxic human umbilical vein endothelial cells (HUVECs) activates complement and induces apoptosis. Role of C5b-9. Exp. Clin. Immunogenet. 1997;14:108 – ABSTRACT ONLY	
	C88	Agah A, Collard CD and Stahl GL. New protein synthesis and NF-κB translocation is required for complement activation on hypoxic/reoxygenated HUVECs. FASEB J. 1998; 12:A28. – ABSTRACT ONLY	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 09/464,303		ATTY. DOCKET NO.: A0752.70001US00	
				FILING DATE: December 15, 1999		CONFIRMATION NO.: 7348	
				APPLICANT: Stahl et al.			
				GROUP ART UNIT: 1644		EXAMINER: Francois P. Vandervegt	
Sheet	2	of	3				

OTHER ART — NON PATENT LITERATURE DOCUMENTS


/PV/	C89	Collard CD, Agah A, Morse DS, Rollins SA, Matis LA; Stahl GL. Reoxygenation of hypoxic HUVECs in human sera augments nuclear NF- κ B translocation and expression of vascular cell adhesion molecule-1 (VCAM-1): Inhibition with anti-human C5 therapy. Molecular Immunology 1998; 35:335. — ABSTRACT ONLY		
	C90	Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Stahl GL, Bunger R, Alving CR. Liposome-induced and complement-mediated cardiopulmonary distress in pigs as a model of pseudo-allergic reactions to liposomal drugs. Molecular Immunology 1998; 35:401. — ABSTRACT ONLY		
	C91	Szebeni J, Stahl GL, Fontana JL, Dobbins D, Mongan PD, Wassef NM, Morse DS, Bunger R, Alving CR. Liposome-induced acute cardiopulmonary distress in swine is mediated by complement. Circulation 1998; 98:1-133— ABSTRACT ONLY		
	C92	Agah A, Young K and Stahl GL. Purification, characterization and cDNA sequencing of porcine mannose-binding lectin (MBL). FASEB J. 1999; 13:A284 — ABSTRACT ONLY		
	C93	Vakeva A, Collard CD, Laine P, Morse DS, Paavonen, Meri S, Kovanen, Stahl GL. Mannose-binding lectin co-localizes with complement in atherosclerotic human coronary arteries: a novel role for the lectin complement pathway in human cardiovascular disease. Molecular Immunology 1999; 36:302— ABSTRACT ONLY		
	C94	Jordan JE, Morrissey M, Stahl GL. Anti-complement treatment protects hypoxic-reoxygenated HUVECs from apoptosis. Immunopharmacology 2000; 49:24— ABSTRACT ONLY		
	C95	Zhao H, Stahl GL. Characterization of monoclonal antibodies (mAb) against native and recombinant human mannose-binding lectin (MBL). Immunopharmacology 2000; 49:83— ABSTRACT ONLY		
	C96	Jordan JE and Stahl GL. Inhibition of mannose binding lectin reduces myocardial reperfusion injury: A role for the lectin complement pathway in cardiovascular disease. JACC 2001; 37:378A— ABSTRACT ONLY		
	C97	Montalto MC Collard CD, Buras JA, Reenstra WR, Geis D, Rother RP, Stahl GL. A peptide mimic of N-acetyl-D-glucosamine inhibits the lectin complement pathway following endothelial oxidative stress. FASEB J. 2001; 15:A339 — ABSTRACT ONLY		
	C98	Zhao H and Stahl GL. Epitope mapping monoclonal antibodies against human mannose binding lectin. FASEB J. 2001; 15:A685— ABSTRACT ONLY		
↓	C99	Jordan JE, Montalto MC, Lopes da Rosa JR, Stahl GL. Regulation of pro-inflammatory genes by the lectin complement pathway following myocardial ischemia-reperfusion. FASEB J. 2001; 15:A463 — ABSTRACT ONLY		

EXAMINER:	DATE CONSIDERED:
-----------	------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 09/464,303

ATTY. DOCKET NO.: A0752.70001US00

FILING DATE: December 15, 1999

CONFIRMATION NO.: 7348

APPLICANT: Stahl et al.

GROUP ART UNIT: 1644

EXAMINER: Francois P. Vandervegt

Sheet

3

of

3

OTHER ART — NON PATENT LITERATURE DOCUMENTS

/PV/	C100	Jordan JE, Morrissey MA, Stahl GL. Isolation and characterization of anti-rat mannose binding lectin antibodies. FASEB J. 2001; 15:A338— ABSTRACT ONLY		
	C101	Mary Walsh, Todd Bourcier, Minoru Takahashi and Gregory Stahl. Complement activation and tissue injury following myocardial ischemia and reperfusion is C1q independent. Molecular Immunology 40: 215, 2003 — ABSTRACT ONLY		
	C102	Deepak Bhole, Todd Bourcier and Gregory Stahl. Anoxia/reoxygenation of rat cardiac myocytes precipitates complement activation. Molecular Immunology 40: 215, 2003 — ABSTRACT ONLY		
	C103	Melanie Hart, Kathleen Ceonzo, Jon Buras and Gregory Stahl. Gastrointestinal ischemia-reperfusion injury is complement-dependent but not dependent on C1q. Molecular Immunology 40: 187, 2003— ABSTRACT ONLY		
	C104	Minoru Takahashi, Dayang Wu, Michelle Giannoni, Russell P. Rother, Gregory L. Stahl Cloning and characterization of recombinant human MASP-2 and the functionally blocking anti-human MBL monoclonal antibody, 3F8. Molecular Immunology 41: 314, 2004— ABSTRACT ONLY		
↓	C105	M.C. Walsh, K. Takahashi, L. Shi, R. Rother, M. Bourgoun, S.D. Solomon, A. Ezekowitz, G.L. Stahl. Complement activation and tissue injury following myocardial ischemia and reperfusion is dependent on MBL. Molecular Immunology 41:322, 2004— ABSTRACT ONLY		

EXAMINER:

/F. Pierre VanderVegt/

DATE CONSIDERED:

03/28/2007

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]